{"filing":{"accession_number":"0001193125-26-385380","cik":"0000730272","ticker":"RGEN","company_name":"REPLIGEN CORP","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-03","primary_document":"d131600d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/730272/000119312526385380/d131600d8k.htm"},"events":[{"id":32093,"run_id":29482,"accession_number":"0001193125-26-385380","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"This Item 8.01 disclosure reports material progress on a previously announced merger: Repligen's acquisition of BioLife Solutions for $11.25 cash and 0.1442 shares per share. The filing confirms that the HSR antitrust waiting period expired on September 3, 2026, removing a key closing condition, and notes that BioLife stockholder approval is scheduled for October 5, 2026. This is a material acquisition activity update that would significantly affect investor assessment of Repligen's strategic direction and capital deployment.","company_name":"REPLIGEN CORP","ticker":"RGEN","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":35177,"accession_number":"0001193125-26-385380","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"This Item 8.01 disclosure reports material progress on a previously announced merger: Repligen's acquisition of BioLife Solutions for $11.25 cash and 0.1442 shares per share. The filing confirms that the HSR antitrust waiting period expired on September 3, 2026, removing a key closing condition, and notes that BioLife stockholder approval is scheduled for October 5, 2026. This is a material acquisition activity update that would significantly affect investor assessment of Repligen's strategic direction and capital deployment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T21:27:42.399248+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35177,"accession_number":"0001193125-26-385380","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"This Item 8.01 disclosure reports material progress on a previously announced merger: Repligen's acquisition of BioLife Solutions for $11.25 cash and 0.1442 shares per share. The filing confirms that the HSR antitrust waiting period expired on September 3, 2026, removing a key closing condition, and notes that BioLife stockholder approval is scheduled for October 5, 2026. This is a material acquisition activity update that would significantly affect investor assessment of Repligen's strategic direction and capital deployment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T21:27:42.399248+00:00","company_name":"REPLIGEN CORP","ticker":"RGEN","filing_date":"2026-09-08"}]}